Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab in Association With the Multipeptide Vaccine IMA950 Adjuvanted With Poly-ICLC for Relapsing Glioblastoma: a Randomized Phase I/ II Trial

NCT03665545 is registered in ClinicalTrials.gov with University Hospital, Geneva as lead sponsor.

NCT NCT03665545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03665545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab in Association With the Multipeptide Vaccine IMA950 Adjuvanted With Poly-ICLC for Relapsing Glioblastoma: a Randomized Phase I/ II Trial
Lead sponsor
University Hospital, Geneva
Phase
Phase 1/2
Overall status
Completed
Start date
October 25, 2018
Completion date
April 24, 2024
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, glioblastoma multiforme of brain, glioblastoma, adult, glioma of brain